Forskning
Udskriv Udskriv
Switch language
Hvidovre Hospital - en del af Københavns Universitetshospital
Udgivet

Long-term outcomes of dexamethasone 12 mg versus 6 mg in patients with COVID-19 and severe hypoxaemia

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Industry sponsorship and research outcome: systematic review with meta-analysis

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Thromboelastography in patients with severe sepsis: a prospective cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Circulating levels of vasoactive peptides in patients with acute bacterial meningitis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Pulse oximetry in severe anaemia.

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskning

  • Anders Granholm
  • Maj-Brit Nørregaard Kjær
  • Marie Warrer Munch
  • Sheila Nainan Myatra
  • Bharath Kumar Tirupakuzhi Vijayaraghavan
  • Maria Cronhjort
  • Rebecka Rubenson Wahlin
  • Stephan M Jakob
  • Luca Cioccari
  • Gitte Kingo Vesterlund
  • Tine Sylvest Meyhoff
  • Marie Helleberg
  • Morten Hylander Møller
  • Thomas Benfield
  • Balasubramanian Venkatesh
  • Naomi E Hammond
  • Sharon Micallef
  • Abhinav Bassi
  • Oommen John
  • Vivekanand Jha
  • Klaus Tjelle Kristiansen
  • Charlotte Suppli Ulrik
  • Vibeke Lind Jørgensen
  • Margit Smitt
  • Morten H Bestle
  • Anne Sofie Andreasen
  • Lone Musaeus Poulsen
  • Bodil Steen Rasmussen
  • Anne Craveiro Brøchner
  • Thomas Strøm
  • Anders Møller
  • Mohd Saif Khan
  • Ajay Padmanaban
  • Jigeeshu Vasishtha Divatia
  • Sanjith Saseedharan
  • Kapil Borawake
  • Farhad Kapadia
  • Subhal Dixit
  • Rajesh Chawla
  • Urvi Shukla
  • Pravin Amin
  • Michelle S Chew
  • Christian Aage Wamberg
  • Neeta Bose
  • Mehul S Shah
  • Iben S Darfelt
  • Christian Gluud
  • Theis Lange
  • Anders Perner
Vis graf over relationer

PURPOSE: We assessed long-term outcomes of dexamethasone 12 mg versus 6 mg given daily for up to 10 days in patients with coronavirus disease 2019 (COVID-19) and severe hypoxaemia.

METHODS: We assessed 180-day mortality and health-related quality of life (HRQoL) using EuroQoL (EQ)-5D-5L index values and EQ visual analogue scale (VAS) in the international, stratified, blinded COVID STEROID 2 trial, which randomised 1000 adults with confirmed COVID-19 receiving at least 10 L/min of oxygen or mechanical ventilation in 26 hospitals in Europe and India. In the HRQoL analyses, higher values indicated better outcomes, and deceased patients were given a score of zero.

RESULTS: We obtained vital status at 180 days for 963 of 982 patients (98.1%) in the intention-to-treat population, EQ-5D-5L index value data for 922 (93.9%) and EQ VAS data for 924 (94.1%). At 180 days, 164 of 486 patients (33.7%) had died in the 12 mg group versus 184 of 477 (38.6%) in the 6 mg group [adjusted risk difference - 4.3%; 99% confidence interval (CI) - 11.7-3.0; relative risk 0.89; 0.72-1.09; P = 0.13]. The adjusted mean differences between the 12 mg and the 6 mg groups in EQ-5D-5L index values were 0.06 (99% CI - 0.01 to 0.12; P = 0.10) and in EQ VAS scores 4 (- 3 to 10; P = 0.22).

CONCLUSION: Among patients with COVID-19 and severe hypoxaemia, dexamethasone 12 mg compared with 6 mg did not result in statistically significant improvements in mortality or HRQoL at 180 days, but the results were most compatible with benefit from the higher dose.

OriginalsprogEngelsk
TidsskriftIntensive Care Medicine
Vol/bind48
Udgave nummer5
Sider (fra-til)580-589
Antal sider10
ISSN0342-4642
DOI
StatusUdgivet - maj 2022

Bibliografisk note

© 2022. Springer-Verlag GmbH Germany, part of Springer Nature.

ID: 76290816